Brain

OmniZare to Unveil Revolutionary Dielectric Tomography Scanners at RSNA 2025

Non-Ionizing Technology Makes Medical Imaging Completely Portable and Ultra-AffordableCHICAGO, Nov. 25, 2025 /PRNewswire/ -- RSNA Booth 8100 – OmniZare, an innovative medical…

2 months ago

Neurophet and The Florey Strengthen Research Collaboration on ‘Neurophet AQUA’ to Advance Alzheimer’s Disease Diagnosis

Aiming to evaluate the utility of blood-based and other biomarkers for Alzheimer's disease diagnosis and managementJoint research to enhance dementia…

2 months ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company…

2 months ago

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025

BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

2 months ago

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Anavex…

2 months ago

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

First publicly listed company to actively investigate psilocybin’s potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) --…

2 months ago

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

November 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (Nasdaq:…

2 months ago

Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates

Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and…

2 months ago

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote “FOR” BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card…

2 months ago